Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia

Hanny Al-Samkari and David J. Kuter

Abstract: The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim and the small molecule agents eltrombopag and avatrombopag. These agents offer a higher clinical response rate than most other ITP therapies but may require indefinite use. This review is a critical appraisal of the TPO-RAs in adult ITP, defining the optimal patient groups to receive these agents and assisting the hematologist with agent choice, goals of treatment, dosing strategies, and toxicity management. Use of endogenous thrombopoietin levels to predict response to eltrombopag and romiplostim treatment is discussed and alternative dosing protocols suited for certain patient subgroups are described. Finally, indications for discontinuation and combination therapy with other agents are considered.

Keywords: avatrombopag, eltrombopag, immune thrombocytopenia, ITP, platelets, romiplostim, thrombopoietin, thrombopoietin receptor agonist

Introduction

Over the past decade, the thrombopoietin receptor agonists (TPO-RAs) have been established as a mainstay in the treatment of immune thrombocytopenia (ITP). TPO-RAs are a class of platelet growth factors that mimic the action of endogenous thrombopoietin (TPO) on megakaryocytes and megakaryocyte precursors, promoting their growth and differentiation and increasing platelet production. In addition to their approval in ITP, these agents have been approved or are under investigation in numerous other thrombocytopenic disorders. Their use in ITP is supported by pathophysiologic studies demonstrating that ITP is characterized by both increased platelet destruction as well as inappropriately low platelet production, with the latter thought secondary to the proapoptotic action of glycoprotein-specific platelet autoantibodies and cytotoxic lymphocytes on megakaryocytes. Therefore, the efficacy of thrombopoietic agents in ITP is attributed to their ability to promote megakaryocyte survival and increase platelet production, thereby improving the platelet count through reversal of the underproduction defect.

There are three TPO-RAs that have been demonstrated to be effective in the management of ITP in multiple phase III studies. Romiplostim (Nplate, Amgen, Thousand Oaks, CA, USA) is a peptide TPO-RA administered subcutaneously on a weekly schedule and eltrombopag (Promacta, Novartis, Basel, Switzerland) and avatrombopag (Doptelet, Dova, Durham, NC, USA) are small molecule TPO-RAs administered orally on a once-daily schedule. Given the numerous available treatment options for patients with ITP, including on-label, off-label, and experimental agents, recognizing when to choose a TPO-RA over immunosuppressive or immunomodulatory agents or splenectomy is important. Similarly, understanding how to choose between the TPO-RAs, their dosing, switching between TPO-RAs, recognizing when discontinuation is appropriate (either because remission has been achieved or clinical response has been inadequate), considering combination therapy in treatment-refractory patients, and managing side effects are essential to the optimal use of these agents. Unfortunately, current guidelines are outdated and give little guidance. This review...
Therapeutic Advances in Hematology 10

Table 1 summarizes the phase III studies examining TPO-RA use in ITP. The decision to initiate a TPO-RA over an immunosuppressive agent or splenectomy is complex and should account for numerous patient and disease-related factors. Overall, TPO-RA have a higher clinical response rate (≥80%) than most other agents (<60%) used in the second-line and beyond, but may require prolonged use. Splenectomized patients who have not previously received a TPO-RA had a response rate of 39–62% in phase III trials that included large numbers of such patients. There is little tachyphylaxis to TPO-RAs in patients with ITP, as responding patients are typically able to maintain a response for extended durations of time. Studies have been published demonstrating durable remissions in a minority of patients treated with TPO-RAs (often treated for extended periods before remission is achieved), although this phenomenon is poorly understood, unpredictable, and may simply represent spontaneous remission that would have occurred in the absence of TPO-RA treatment. Therefore, patients in whom compliance is a concern, who dislike taking medication on a chronic basis, who desire treatments with a higher likelihood of treatment-free remission, or those with limited access to TPO-RAs are best treated with other agents. In the second-line setting, the typical alternatives to TPO-RAs include rituximab and splenectomy. Given that a significant minority of adults with ITP will achieve remission with medical therapy during the first year following diagnosis, the authors prefer to use medical therapies for at least 1 year before considering splenectomy in most adult patients with ITP. In one study, one-third of nonsplenectomized patients with acute or persistent ITP achieved remission when treated with romiplostim for up to 1 year.

As eltrombopag is potentially hepatotoxic and its use has been associated with venous thromboembolism (VTE) in patients with chronic liver disease, avoidance of this agent in patients with ITP with chronic liver disease is advised. There are few published data regarding the safety of romiplostim in the chronic liver disease population. Avatrombopag has been extensively studied in chronic liver disease patients without ITP and has not demonstrated significant hepatotoxicity or increased VTE risk in this patient group.

Recent data have emerged demonstrating an inverse relation between the endogenous TPO level and response to treatment with eltrombopag and romiplostim in patients with ITP. Lower endogenous TPO levels predicted improved probability and depth of response to these two agents. In those patients with a normal baseline TPO level (<100 pg/ml, as assessed by the only currently commercially available assay validated for clinical use, an enzyme-linked immunosorbent assay-based test from Quest Diagnostics, San Juan Capistrano, CA, USA), likelihood of robust response to either agent was high. In contrast, patients with significant TPO elevations (>200 pg/ml) were unlikely to have a satisfactory response to either agent, suggesting that these patients may be better managed with other modalities. Figure 1 illustrates a predictive model of response fraction (fraction of measured platelet counts on TPO-RA treatment that are ≥50 × 10^9/l and ≥20 × 10^9/l higher than pretreatment baseline) based on the TPO level. Given these data, TPO level measurement can be considered for patients in whom TPO receptor agonist treatment is anticipated to help guide clinical decision making. Due to the turn-around time of this send-out assay it is best assessed in advance of the need to initiate therapy, and it can be readily measured at any point as TPO levels in patients with ITP do not appear to be significantly affected by platelet count, disease duration, or receipt of ITP-directed therapies.

Who to treat with a thrombopoietin receptor agonist

Approval for TPO-RAs in ITP is currently limited to those patients with chronic ITP (disease duration of 1 year or more, in contrast with acute ITP and persistent ITP in which disease duration is <3 months and 3–12 months, respectively) who have failed treatment with glucocorticoids, splenectomy, or intravenous immunoglobulin (IVIG). It is important to note that in many of the pivotal studies, ITP was considered chronic if present for over 6 months. Despite this, use of these agents for patients with acute or persistent ITP is frequent in clinical practice and first-line use is under investigation. Indeed, a recent meta analyses of all romiplostim studies demonstrated that the response rates and adverse event profiles were virtually identical for patients with ITP for <1 year (with acute or persistent disease) and patients with ITP for ≥1 year.

Table 1 summarizes the phase III studies examining TPO-RA use in ITP. The decision to initiate a TPO-RA over an immunosuppressive agent or splenectomy is complex and should account for numerous patient and disease-related factors. Overall, TPO-RAs have a higher clinical response rate (≥80%) than most other agents (<60%) used in the second-line and beyond, but may require prolonged use. Splenectomized patients who have not previously received a TPO-RA had a response rate of 39–62% in phase III trials that included large numbers of such patients. There is little tachyphylaxis to TPO-RAs in patients with ITP, as responding patients are typically able to maintain a response for extended durations of time. Studies have been published demonstrating durable remissions in a minority of patients treated with TPO-RAs (often treated for extended periods before remission is achieved), although this phenomenon is poorly understood, unpredictable, and may simply represent spontaneous remission that would have occurred in the absence of TPO-RA treatment. Therefore, patients in whom compliance is a concern, who dislike taking medication on a chronic basis, who desire treatments with a higher likelihood of treatment-free remission, or those with limited access to TPO-RAs are best treated with other agents. In the second-line setting, the typical alternatives to TPO-RAs include rituximab and splenectomy. Given that a significant minority of adults with ITP will achieve remission with medical therapy during the first year following diagnosis, the authors prefer to use medical therapies for at least 1 year before considering splenectomy in most adult patients with ITP. In one study, one-third of nonsplenectomized patients with acute or persistent ITP achieved remission when treated with romiplostim for up to 1 year.

As eltrombopag is potentially hepatotoxic and its use has been associated with venous thromboembolism (VTE) in patients with chronic liver disease, avoidance of this agent in patients with ITP with chronic liver disease is advised. There are few published data regarding the safety of romiplostim in the chronic liver disease population. Avatrombopag has been extensively studied in chronic liver disease patients without ITP and has not demonstrated significant hepatotoxicity or increased VTE risk in this patient group.

Recent data have emerged demonstrating an inverse relation between the endogenous TPO level and response to treatment with eltrombopag and romiplostim in patients with ITP. Lower endogenous TPO levels predicted improved probability and depth of response to these two agents. In those patients with a normal baseline TPO level (<100 pg/ml, as assessed by the only currently commercially available assay validated for clinical use, an enzyme-linked immunosorbent assay-based test from Quest Diagnostics, San Juan Capistrano, CA, USA), likelihood of robust response to either agent was high. In contrast, patients with significant TPO elevations (>200 pg/ml) were unlikely to have a satisfactory response to either agent, suggesting that these patients may be better managed with other modalities. Figure 1 illustrates a predictive model of response fraction (fraction of measured platelet counts on TPO-RA treatment that are ≥50 × 10^9/l and ≥20 × 10^9/l higher than pretreatment baseline) based on the TPO level. Given these data, TPO level measurement can be considered for patients in whom TPO receptor agonist treatment is anticipated to help guide clinical decision making. Due to the turn-around time of this send-out assay it is best assessed in advance of the need to initiate therapy, and it can be readily measured at any point as TPO levels in patients with ITP do not appear to be significantly affected by platelet count, disease duration, or receipt of ITP-directed therapies.
Which thrombopoietin receptor agonist to select

Currently, only romiplostim and eltrombopag are United States Food and Drug Administration (US FDA)-approved for the treatment of chronic ITP, although a supplemental new drug application has been accepted by the US FDA for the use of avatrombopag to treat chronic ITP. Therefore,
this agent may be approved for ITP in the future. The pharmacologic characteristics of these TPO-RAs are compared in Table 2.

Although each of these agents demonstrates comparable initial overall response rates, several considerations impact agent selection. Eltrombopag and avatrombopag offer the convenience of oral administration, compared with romiplostim which usually requires weekly clinic visits for subcutaneous administration. The patient’s insurance coverage may dictate which agent is covered. Eltrombopag absorption is severely impacted by consumption of fat or divalent cations, essentially requiring a 4-hour fasted window around its administration (6 h if 50 mg calcium is consumed, an amount which is present in a single serving of numerous dairy, grain, and vegetable products) otherwise its effectiveness may be compromised.34,35 In contrast, avatrombopag may be taken with or without food (and absorption is actually optimized when taken with food).36,37 Patients with modest elevations in baseline endogenous TPO level (TPO 100–200 pg/ml) may respond better to romiplostim than eltrombopag (Figure 1).30 While response to avatrombopag has been shown to be impacted by baseline TPO level in patients with thrombocytopenia of chronic liver disease,38 studies have not yet assessed the role of TPO levels in predicting avatrombopag response in patients with ITP. The higher rates of clinical response to romiplostim over eltrombopag observed in patients with TPO level elevations may be related to agent potency. In healthy volunteers, maximal doses of romiplostim and avatrombopag produced peak platelet counts 8–10 times higher and 3–5 times higher, respectively, than maximal doses of eltrombopag.36,39,40 Figure 2 demonstrates the relative potency of each of these three agents in an ITP patient who received all three drugs.41

Cost is an important consideration when deciding to use TPO-RA treatment, as these agents remain expensive. In consideration of which agent is more cost effective, US-based cost-effectiveness analyses comparing eltrombopag with romiplostim have reported conflicting results (one favoring eltrombopag and the other favoring romiplostim).42,43 The average wholesale price in the US for each of the three agents is given in Table 2.

How to dose thrombopoietin receptor agonists

**Romiplostim**

The prescribing information recommends an initial dose of 1 µg/kg/week, with sequential increases of 1 µg/kg each week to achieve a platelet count ≥50 × 10^9/l.13 In clinical practice, however, patients are frequently initiated at a higher dose to shorten the time required to titrate to a patient’s optimized dose.44 Evidence suggests this is well tolerated, since in a large study including 120 patients with ITP initiated at ≥2 µg/kg/week the rate of thrombocytosis was only 4%.44 Additionally, in a phase III study of romiplostim, all patients were initiated at a dose of 3 µg/kg/week.1 Initiation at even higher doses in patients with glucocorticoid and IVIG-refractory disease and acute bleeding symptoms may also be prudent. In a small study of hospitalized patients with refractory ITP who were initiated on romiplostim, initiating romiplostim at ≥2 µg/kg/week (median starting dose of 4.5 µg/kg/week) resulted in less bleeding, shorter hospital length of stay, and higher likelihood of achieving a platelet count ≥50 × 10^9/l with no thrombotic events, than initiating romiplostim at 1 µg/kg/week.45 The authors routinely start most patients at 3 µg/kg/week, 5 µg/kg/week if severely thrombocytopenic, and occasionally at 10 µg/kg/week for an initial two doses in cases of clinical emergencies (such as bleeding with profound thrombocytopenia).
Table 2. Comparison of the TPO-RAs used in ITP treatment.

|                      | Romiplostim | Eltrombopag                   | Avatrombopag     |
|----------------------|-------------|-------------------------------|------------------|
| Molecular structure  | Peptide     | Small molecule                | Small molecule   |
| TPO receptor site of action | Extracellular domain | Transmembrane domain | Transmembrane domain |
| Route of administration | Subcutaneous | Oral                         | Oral             |
| Dosing frequency     | Weekly      | Daily                         | Daily            |
| Relevant food interactions | N/A         | Yes                           | No               |
| Average USD wholesale price | $2165.34 per 250 µg vial | $182.46 per tablet (12.5 mg or 25 mg) | $1132.80 per 20 mg tablet |
|                      | $4330.68 per 500 µg vial | $330.20 per tablet (50 mg) | $495.30 per tablet (75 mg) |
| Current indications  | Chronic ITP (adults and children) | Chronic ITP (adults and children) | Periprocedural thrombocytopenia in patients with CLD |
|                      | Chronic ITP (adults and children) | Hepatitis C-associated thrombocytopenia | Severe aplastic anemia |
|                      | Chemotherapy-induced thrombocytopenia | Inherited thrombocytopenia | Chronic ITP (adults) |
|                      | Perioperative thrombocytopenia | Perioperative thrombocytopenia | Chemotherapy-induced thrombocytopenia |

aPer drug label.
CLD, chronic liver disease; ITP, immune thrombocytopenia; N/A, not applicable; TPO, thrombopoietin; TPO-RA, thrombopoietin receptor agonist.

Figure 2. Relative potency of eltrombopag (E), avatrombopag (A), and romiplostim (R) in a patient with ITP. The magnitude of response of this ITP patient to each of these TPO-RAs is comparable to what is seen in healthy volunteers. Dosing for each agent is given above the platelet trend line, and median platelet counts for each agent in this patient are given in the inset bar graph. Reproduced from Al-Samkari and Kuter.41
ITP, immune thrombocytopenia.
Likewise, the authors typically increase the dose by more than 1 µg/kg at a time in nonresponding or poorly responding patients, a rate faster than advised in the prescribing information. The gradual rate of romiplostim dose escalation described in the prescribing information may result in longer durations of profound thrombocytopenia and an increased bleeding risk, whereas more rapid dose escalation presents a risk of thrombocytosis (and a theoretical risk of thromboembolism). The clinician should weigh these risks in determining a rate of dose escalation most appropriate for a given patient.

The prescribing information advises withholding a dose if platelet count is >400 × 10^9/l. However, up to 15% of patients so treated will have a rebound thrombocytopenia to below their prior baseline which may increase their risk of bleeding. While no studies have been published comparing dose reduction and dose withholding in patients with thrombocytosis, our experience is that dose reduction (typically a dose reduction of one-third to two-thirds) is effective in eliminating thrombocytosis with considerably less platelet count fluctuation than with dose withholding.

**Eltrombopag**

The recommended initial dose of eltrombopag is 50 mg daily in all patients except those of East Asian ethnicity, those with chronic liver disease and children 1–5 years of age, in whom the recommended initial dose is 25 mg daily. Dose increase by one tablet strength (to a maximum of 75 mg) is advised for platelet count <50 × 10^9/l and dose reduction by one tablet strength (to a minimum of 12.5 mg) is advised for platelet count ≥200 × 10^9/l to <400 × 10^9/l. Although used at higher doses in aplastic anemia (150 mg daily), there are few data to support dose escalation to this level in patients with ITP.

Many patients may struggle with the dietary requirements to ensure adequate eltrombopag absorption and may not be fully compliant with the required 4–6 h window of food avoidance. Adhering to the food avoidance window is not trivial given that many patients may receive this agent for extended time periods. In compliant patients with robust platelet count responses to eltrombopag who struggle with dietary quality of life issues, alternative intermittent (AI) eltrombopag dosing may be considered. AI dosing utilizes intermittent eltrombopag dosing 1–5 times weekly rather than daily dosing (Figure 3), usually using the 75 mg dose. Given the kinetics of thrombopoiesis and the 26–35 h half-life of eltrombopag in patients with ITP, dosing less frequently than once daily is rational. Beyond quality of life issues, AI dosing may also be appropriate in lieu of prescribing information dose-reduction instructions and may be an option for use of eltrombopag in resource-poor settings. It is also a suitable option for the slow tapering of this agent.

---

**Figure 3.** Alternative intermittent eltrombopag dosing protocol. Protocol for administration of eltrombopag less frequently than once daily in patients who poorly tolerate daily dietary restrictions. Can also be used to taper eltrombopag. Reproduced from Al-Samkari and Kuter. 

Plt, platelet; QOD, every other day.
Similar to romiplostim, the eltrombopag prescribing information advises withholding drug for platelet counts $\geq 400 \times 10^9/l$.\textsuperscript{14} Except in cases of extreme thrombocytosis, we opt for AI dosing or dose reduction in this setting as an alternative to withholding the drug to avoid a precipitous drop in the platelet count.

**Avatrombopag**

As avatrombopag is not yet approved for ITP, specific dosing recommendations are not currently available. In a phase II trial of avatrombopag, a daily dose of 5 or 10 mg daily achieved a platelet response (defined as a platelet count $\geq 50 \times 10^9/l$ with $\geq 20 \times 10^9/l$ increase above baseline) in approximately half of patients, and a dose of 20 mg daily achieved a platelet response in 80%\textsuperscript{47}. This 20 mg dose was used in a subsequent phase III trials with similarly robust response rates.\textsuperscript{11}

**What adverse events occur and how to monitor for them**

TPO-RAs are generally well-tolerated agents. In clinical trials of adult patients with ITP, the most commonly observed nonbleeding-related adverse events of eltrombopag were gastrointestinal symptoms (nausea, vomiting, diarrhea), mild transaminase elevations, and headache.\textsuperscript{2} In trials of romiplostim, headache, arthralgia, myalgia, dizziness and insomnia were the most commonly reported symptoms.\textsuperscript{1} In avatrombopag trials, headache, fatigue, arthralgia and diarrhea were most commonly reported.\textsuperscript{11} The most common adverse event overall was mild to moderate headache, which is typically managed with acetaminophen and dose reduction as necessary. Because of the risk of hepatotoxicity with eltrombopag, liver enzymes and bilirubin should be monitored every 2 weeks during dose optimization and monthly thereafter, with discontinuation of the agent for significant transaminase or bilirubin elevations.\textsuperscript{14} Many such patients may resume eltrombopag at a lower dose or altered frequency upon recovery from the hepatic insult.

Thrombotic events and bone marrow fibrosis are the potential adverse events of greatest concern with the use of TPO-RAs in patients with ITP. Although thrombotic events were not observed, the thrombotic potential of pharmacologic administration of thrombopoietic agents was suggested by the marked thrombocytosis observed in otherwise healthy nonhuman primates exposed to recombinant thrombopoietins.\textsuperscript{48,49} However, studies examining the function of platelets from human patients with ITP treated with eltrombopag\textsuperscript{50} and romiplostim\textsuperscript{51} showed no evidence of platelet hyperreactivity or spontaneous platelet aggregation. To the contrary, there appeared to be a defect in the platelet aggregation response to adenosine diphosphate and epinephrine (likely due to platelet autoantibodies rather than the effect of the drug) in the platelets of patients with ITP despite treatment with romiplostim.\textsuperscript{51} It is well recognized that ITP is itself a prothrombotic state,\textsuperscript{52–54} but the numerous large controlled studies of patients with ITP receiving the TPO-RAs have not demonstrated a significantly increased of arterial or venous thrombotic risk over those treated with placebo.\textsuperscript{1,2,55,56} Of note, these trials had relatively short observation periods. Longer-term nonrandomized observational studies have suggested a modestly higher rate of thrombosis in patients with ITP treated with TPO-RAs as compared with similar observational studies of patients with ITP treated with immunosuppressive agents.\textsuperscript{57,58} Therefore, the thrombotic potential of TPO-RAs should be a consideration in patients with ITP with significant risk factors for venous or arterial thrombosis.

In the chronic liver disease population, there is stronger evidence of a possible increased propensity to VTE with TPO-RA use. In two studies of eltrombopag use in patients with chronic liver disease (one examining treatment of periprocedural thrombocytopenia\textsuperscript{59} and the other examining treatment of hepatitis C-associated thrombocytopenia\textsuperscript{3}), there was an apparent increased rate of VTE (and portal vein thrombosis in particular) in patients receiving eltrombopag. This was not seen, however, in studies of avatrombopag and lusutrombopag to treat periprocedural thrombocytopenia in chronic liver disease patients,\textsuperscript{59–61} although these studies were not specifically powered to detect a difference in VTE rate between TPO-RA and placebo-treated patients, and treatment was for a brief period of time.

Therefore, if a thrombotic event occurs in an ITP patient receiving TPO-RA treatment, assessment of thrombotic risk factors should occur as in any patient presenting with a new thrombosis. If
Therapeutic Advances in Hematology 10

Therapeutic Advances in Hematology 10

provoking risk factors (e.g. atherosclerosis, obesity, surgery, trauma, or prolonged immobility) are not identified, it may be reasonable to switch to another ITP treatment such as immunosuppression, even if the TPO-RA cannot be accountable for the thrombotic event. This is done with the recognition that a stable platelet count is necessary for the anticoagulation of the patient. If other ITP treatments are known to be ineffective and TPO-RAs are required to maintain a safe platelet count for anticoagulation, they should be continued for this purpose with close monitoring. It is not appropriate to forego anticoagulation in patients with ITP with thrombosis because of thrombocytopenia unless the disease is refractory to all treatments and a minimally acceptable platelet count (e.g. \( \geq 20 \times 10^9/l \)) cannot be achieved.

While bone marrow fibrotic complications remain a potential risk of TPO-RAs, examination of a large number of patients treated with these agents for extended periods of time revealed a very low risk of reversible marrow reticulin fibrosis and essentially no increased risk of more serious, usually irreversible collagen fibrosis.\(^{62,63}\) Therefore, bone marrow biopsy prior to TPO-RA initiation or serial bone marrow biopsies in patients maintained on TPO-RAs for extended periods are not needed. Similarly, while bone marrow blast percentages may rise in patients with myelodysplastic syndromes treated with TPO-RAs, this reverses upon discontinuation of the agent and there is no increased risk of progression to acute myeloid leukemia even with several years of follow up.\(^{64}\) The risk of myeloid malignancies in patients with ITP receiving treatment with TPO-RAs has not been rigorously studied, although an increased rate has not been observed in currently published randomized or observational studies.

**How to define treatment success**

As the ultimate objective of TPO-RA treatment is to prevent bleeding, a target platelet count between \( 50 \times 10^9/l \) and \( 150 \times 10^9/l \) is appropriate in the majority of patients. However, many patients with severe disease rarely or never achieve a platelet count \( \geq 50 \times 10^9/l \) and more modest goals, such as a platelet count \( \geq 20 \times 10^9/l \), are acceptable in these patients in the absence of bleeding symptoms.

There is rarely a need to normalize the platelet count, but this situation may arise in patients undergoing major cardiovascular or neurological surgery. In the event a surgeon requests normalization of the platelet count in a patient with ITP due to a perceived high surgical bleeding risk, TPO-RA treatment is capable of achieving this in the vast majority of patients with ITP.\(^{7,65}\) Additionally, fatigue is a very common symptom in patients with ITP, and may correlate with the platelet count.\(^{66}\) Although fatigue is frequently challenging to assess, validated instruments for this population are available.\(^{67}\) While data are lacking, normalization of the platelet count with TPO-RA treatment in patients with ITP suffering from severe fatigue may be considered as a therapeutic trial to treat fatigue.\(^{68}\)

**When to consider discontinuation or combination therapy**

Discontinuation of TPO-RA management may be considered in the setting of treatment failure, unacceptable adverse events (such as thromboembolism or liver injury), or remission. The prescribing information advises discontinuation of therapy if no hematologic response is seen after 16 weeks of treatment with eltrombopag or 4 weeks of treatment at maximal dose of romiplostim.\(^{13,14}\) When contemplating TPO-RA discontinuation for nonresponse, two strategies may be attempted. The first is a switch between agents, as for unclear reasons some patients who fail to respond to one TPO-RA may respond to another.\(^{69}\) The second is the addition of low-dose prednisone, 5–15 mg daily. Addition of low-dose prednisone to TPO-RA treatment may achieve a response in some patients for whom maximal dose TPO-RA alone has failed.\(^{30}\)

Given the risk of rebound thrombocytopenia following discontinuation of romiplostim in approximately 10–15% of patients with ITP who have demonstrated a response,\(^{70}\) a gradual wean over 2–4 weeks is reasonable. Despite the lack of more definitive data describing rebound thrombocytopenia with oral TPO-RAs, we also taper responsive patients with ITP receiving eltrombopag or avatrombopag. This practice has not yet been assessed in a clinical study, however.

Determining when a patient has achieved remission while on TPO-RA therapy can sometimes be challenging, especially in patients well controlled for extended periods of time on low-dose therapy. A recent study demonstrated that absence of
direct glycoprotein-specific platelet autoantibodies was 88% sensitive and 91% specific for a clinical remission of ITP (a negative test had a positive likelihood ratio of 9.5 for remission).71 Despite the fact that TPO-RAs are not immune-modulating agents, there appears to be a small fraction of patients who achieve remission with use of these agents (although it is possible that these are coincidental spontaneous remissions).24,25 Therefore, the need for continuing TPO-RA therapy should be assessed frequently. Remission should be considered in patients with an increasing platelet count or new thrombocytosis in the setting of repeated dose reductions of the TPO-RA. In this setting, discontinuation via a short taper (or the AI dosing protocol for eltrombopag-treated patients, Figure 3) is a reasonable course of action. The opposite scenario, in which a patient on romiplostim loses a response that had been previously maintained over time, should prompt consideration of very rare neutralizing anti-drug antibodies.72 In this setting, blood samples can be sent to the drug manufacturer (Amgen, Thousand Oaks, CA, USA) for the evaluation of this possibility.

TPO-RAs are an attractive choice for combination therapy in ITP, as their unique mechanism of action among the ITP therapies of augmenting platelet production may synergize with agents that diminish platelet destruction, either via decreased platelet clearance (e.g. glucocorticoids and dexamethasone) or reduction in platelet autoantibody production (e.g. cyclophosphamide, rituximab or azathioprine).20 Any of the TPO-RAs can be used as part of combination therapy in treatment-resistant or treatment-refractory patients,13,14,73 but evidence evaluating each of the potential combinations is sparse. Given that romiplostim and the small molecule TPO-RAs act on different domains of the TPO receptor c-Mpl (Table 2), administration of dual-agent TPO-RA therapy could theoretically have additive or synergistic effect and achieve a response in a patient who fails to respond to single-agent therapy. Data are lacking for this approach, however, and it is difficult to justify the financial cost of two expensive agents simultaneously if other viable therapeutic combinations are possible. Finally, combination TPO-RA plus glucocorticoid therapy is under evaluation in the upfront setting, with the aim of increasing early remission rates and lowering the likelihood of progression to chronic ITP.18 Currently this approach is still experimental.

**Conclusion**

TPO-RAs currently represent a reliable second-line ITP treatment with a relatively high response rate and few adverse effects. Measurement of the baseline endogenous TPO level prior to TPO-RA initiation can guide selection of TPO-RAs over other treatment as well as selection of one TPO-RA over another. Many other factors, such as route of administration preference, dietary restrictions, and potency considerations may also impact agent selection. The goal of treatment is a platelet count sufficient to prevent bleeding rather than a normalized platelet count. TPO-RAs are generally well tolerated, with headache as the most frequently reported adverse effect. Importantly, large clinical trials have not demonstrated an increased rate of thromboembolism or appreciable risk of bone marrow fibrosis in patients treated with TPO-RAs. Finally, recognition that TPO-RA treatment may be associated with remission in a subset of patients is encouraging and the search for patient or disease characteristics that predict an increased likelihood of remission will allow for further optimization of our use of these agents in clinical practice.

**Acknowledgements**

H.A. is the recipient of the National Hemophilia Foundation-Shire Clinical Fellowship Award, which provides partial salary support.

H.A. drafted the manuscript, created the tables and figures, and contributed to concept and design, critical revision of the intellectual content, and final approval. D.J.K. contributed to concept and design, critical revision of the intellectual content, and final approval.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Conflict of interest statement**

Dr Al-Samkari reports a consultancy (Agios). Dr Kuter reports research funding (Protalex, Bristol-Myers Squibb, Rigel, Bioverativ, Agios, Syntimmune, Principia, Alnylam) and consultancy (ONO, Pfizer, 3SBios, Eisai, GlaxoSmithKline, Genzyme, Shire, Alexion, Amgen, Shionogi, Rigel, Syntimmune, MedImmune, Novartis, Bioverativ, Argenx, Zafgen).
References

1. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. *N Engl J Med* 2010; 363: 1889–1899.

2. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. *Lancet* 2011; 377: 393–402.

3. Kuter DJ and Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. *Hematol Oncol Clin North Am* 2009; 23: 1193–1211.

4. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. *Blood* 2014; 123: 1818–1825.

5. Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. *Gastroenterology* 2014; 146: 442–452 e441.

6. Al-Samkari H, Marshall AL, Goodarzi K, et al. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. *Haematologica* 2018; 103: e169–e172.

7. Al-Samkari H, Marshall AL, Goodarzi K, et al. Romiplostim for the management of perioperative thrombocytopenia. *Br J Haematol* 2018; 182: 106–113.

8. Harrington WJ, Minnich V, Hollingsworth JW, et al. Demonstration of a thrombopoietic factor in the blood of patients with thrombocytopenic purpura. *J Lab Clin Med* 1951; 38: 1–10.

9. Harker LA and Finch CA. Thrombokinetics in man. *J Clin Invest* 1969; 48: 963–974.

10. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. *Blood* 2004; 103: 1364–1369.

11. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. *Br J Haematol* 2018; 183: 479–490.

12. Pharmaceuticals D. Doptelet (avatrombopag) tablets: US prescribing information. 2018.

13. Amgen I. Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen, 2017.

14. GlaxoSmithKline. Promacta (eltrombopag) [prescribing information]. NC: Research Triangle Park, 2017.

15. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood* 2011; 117: 4190–4207.

16. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood* 2010; 115: 168–186.

17. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood* 2009; 113: 2386–2393.

18. Zhang L, Zhang M, Du X, et al. Eltrombopag plus pulsed dexamethasone as first line therapy for subjects with Immune Thrombocytopenic Purpura (ITP). *Blood* 2018; 132(Suppl. 1): 733.

19. Kuter DJ, Newland A, Chong BH, et al. Comparison of the effects of the thrombopoietin (TPO) receptor agonist romiplostim in patients with immune thrombocytopenia (ITP) for ≤1 year vs. >1 year. *Blood* 2017; 130(Suppl. 1): 1055.

20. Cuker A and Neunert CE. How I treat refractory immune thrombocytopenia. *Blood* 2016; 128: 1547–1554.

21. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. *Lancet* 2008; 371: 395–403.

22. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. *Lancet* 2009; 373: 641–648.

23. Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. *Br J Haematol* 2013; 161: 411–423.

24. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. *Br J Haematol* 2016; 172: 262–273.

25. Gonzalez-Lopez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of
eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015; 90: E40–E43.

26. Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012; 10: 799–806.

27. Yang R, Hou M, Li J, et al. Effect of eltrombopag on platelet response and safety results in Chinese adults with chronic ITP-primary result of a phase III study. Blood 2014; 124: 1464.

28. Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 2011; 94: 71–80.

29. Afdhal NH, Giannini EG, Tayyab G, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after Pfos. Clin Ther 2012; 34: 699–709.

30. Al-Samkari H and Kuter DJ. Thrombopoietin concentrations and response to romiplostim in Japanese patients with previously treated chronic liver disease. Drugs Today (Barc) 2018; 54: 647–655.

31. Nomoto M, Ferry J and Hussein Z. Population pharmacokinetic/pharmacodynamic analyses of avatrombopag in patients with chronic liver disease and optimal dose adjustment guide with concomitantly administered CYP3A and CYP2C9 inhibitors. J Clin Pharmacol 2018; 58: 1629–1638.

32. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739–4741.

36. Nomoto M, Pastino G, Rege B, et al. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev 2018; 7: 188–195.

37. Al-Samkari H. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease. Drugs Today (Barc) 2018; 54: 647–655.

38. Nomoto M, Ferry J and Hussein Z. Population pharmacokinetic/pharmacodynamic analyses of avatrombopag in patients with chronic liver disease and optimal dose adjustment guide with concomitantly administered CYP3A and CYP2C9 inhibitors. J Clin Pharmacol 2018; 58: 1629–1638.

39. Kugamag Y, Fujita T, Ozaki M, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 2007; 47: 1489–1497.

40. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739–4741.

41. Al-Samkari H and Kuter DJ. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haematol 2018; 183: 168.

42. Tremblay G, Dolph M, Bhor M, et al. Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. Clinicoecon Outcomes Res 2018; 10: 705–713.

43. Fust K, Parthan A, Li X, et al. Cost per response analysis of strategies for chronic immune thrombocytopenia. Am J Manag Care 2018; 24: SP294–SP302.

44. Steurer M, Quittet P, Papadaki HA, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. Eur J Haematol 2017; 98: 112–120.

45. DasGupta RK, Levine L, Wiczer T, et al. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia. J Oncol Pharm Pract. Epub ahead of print 3 January 2018. DOI: 10.1177/1078155217748470.

46. Al-Samkari H and Kuter DJ. An alternative intermittent eltrombopag dosing protocol for the
treatment of chronic immune thrombocytopenia. *Br J Clin Pharmacol* 2018; 84: 2673–2677.

47. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. *Blood* 2014; 123: 3887–3894.

48. Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. *Blood* 1996; 87: 1833–1844.

49. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. *Blood* 1996; 88: 511–521.

50. Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. *Blood* 2012; 119: 4066–4072.

51. Al-Samkari H, Van Cott EM and Kuter DJ. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. *Ann Hematol.* Epub ahead of print 17 November 2018. DOI: 10.1007/s00277-018-3556-6.

52. Sarpawari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. *Haematologica* 2010; 95: 1167–1175.

53. Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. *Br J Haematol* 2011; 152: 360–362.

54. Langeberg WJ, Schoonen WM, Eisen M, et al. Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies. *Int J Hematol* 2016; 103: 655–664.

55. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. *Blood* 2009; 113: 2161–2171.

56. Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. *Int J Hematol* 2015; 102: 250–270.

57. Nguyen TT, Palmaro A, Montastruc F, et al. Signal for thrombosis with eltrombopag and romiplostim: a disproportionality analysis of spontaneous reports within VigiBase(R). *Drug Saf* 2015; 38: 1179–1186.

58. Vishnu P and Aboulafia DM. Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. *J Blood Med* 2016; 7: 99–106.

59. Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. *Gastroenterology* 2018; 155: 705–718.

60. Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. *Clin Gastroenterol Hepatol.* Epub ahead of print 28 November 2018. DOI: 10.1016/j.cgh.2018.11.047.

61. Tateishi R, Seike M, Kudo M, et al. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. *J Gastroenterol.* Epub ahead of print 13 August 2018. DOI: 10.1007/s00535-018-1499-2.

62. Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. *Blood* 2009; 114: 3748–3756.

63. Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. *Ann Hematol* 2016; 95: 1077–1087.

64. Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. *Lancet Haematol* 2018; 5: e117–e126.

65. Nagrebetsky A, Al-Samkari H, Davis NM, et al. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. *Br J Anaesth* 2019; 122: 19–31.

66. Newton JL, Reese JA, Watson SI, et al. Fatigue in adult patients with primary immune thrombocytopenia. *Blood* 2014; 123: 3887–3894.

67. Signorovitch J, Brainsky A and Grotzinger KM. Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. *Gastroenterology* 2018; 155: 705–718.
thrombocytopenia. *Qual Life Res* 2011; 20: 1737–1744.

68. Hill QA and Newland AC. Fatigue in immune thrombocytopenia. *Br J Haematol* 2015; 170: 141–149.

69. Kuter DJ, Macahilig C, Grotzinger KM, *et al.* Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. *Int J Hematol* 2015; 101: 255–263.

70. Bussel JB, Kuter DJ, George JN, *et al.* AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. *N Engl J Med* 2006; 355: 1672–1681.

71. Al-Samkari H and Kuter DJ. Antiplatelet antibody testing in immune thrombocytopenia and evans syndrome: longitudinal serologic evolution and relation to clinical features. *Blood* 2018; 132(Suppl. 1): 1137.

72. Barger TE, Boshier A, Jawa V, *et al.* Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global registry. *Blood* 2018; 132(Suppl. 1): 2427.

73. Gomez-Almaguer D. Eltrombopag-based combination treatment for immune thrombocytopenia. *Ther Adv Hematol* 2018; 9: 309–317.